Does Semaglutide Affect Your Heart — and Is That a Good or a Bad Thing?

The biggest misconception: that semaglutide is risky for the heart

When people search this question, they often expect the answer to be a warning. In fact, the evidence points the other way. The SELECT trial (a large randomised controlled study published in the New England Journal of Medicine) enrolled more than 17,000 adults who had established cardiovascular disease and a BMI of 27 or above, but no history of diabetes. Over an average of around five years, those taking semaglutide 2.4mg had roughly 20% fewer major adverse cardiovascular events (heart attacks, strokes and cardiovascular death) than those on placebo. That result was significant enough that the MHRA granted semaglutide a second licensed indication specifically for cardiovascular risk reduction, distinct from its weight-management licence.

It is a reasonable misconception to have. GLP-1 medicines are relatively new, and the early conversation in the press focused mostly on side effects. The cardiovascular benefit tends to get less attention, which is unfortunate, because for people who both carry excess weight and have a heart condition, it changes the conversation considerably.

That protective signal likely comes from more than weight loss alone. Researchers believe semaglutide acts on inflammation, blood pressure, lipid profiles and possibly direct cardiac tissue pathways, though the precise mechanisms are still being studied. The weight reduction itself also reduces cardiovascular load over time.

The one genuine cardiac side effect: a modest rise in resting heart rate

There is one cardiovascular effect that genuinely warrants attention, and it appears consistently across semaglutide trials: a small increase in resting heart rate, typically in the range of one to four beats per minute. For the vast majority of people this is clinically unremarkable, but it is worth knowing about.

The NHS medicines page for semaglutide lists heart palpitations among the possible side effects to be aware of. If you notice your heart racing or beating irregularly after starting or increasing your dose, that is worth reporting to your prescriber rather than waiting for a routine review. It does not mean the medicine is damaging your heart, but a clinician should know about it.

People with pre-existing arrhythmias or other structural heart conditions will be assessed more carefully at the consultation stage precisely because of this. A prescriber who reviews your medical history before issuing a prescription is not a formality, it is how individual risks like this get caught and accounted for. Our clinical team at nume reviews each consultation personally, not via automated decision-making.

The palpitation signal tends to be most noticeable in the first few weeks at a new dose and often settles as the body adjusts. It is not a reason to stop treatment without speaking to a clinician first.

What the cardiovascular licence actually covers, and what it does not

Since the SELECT results, Wegovy carries a UK licence for two distinct uses: weight management (BMI 30 or above, or 27 with a weight-related condition), and reduction of major cardiovascular events in adults with existing cardiovascular disease and BMI 30 or above. These are separate indications. You do not need the cardiovascular indication to use Wegovy for weight management, and having heart disease does not automatically mean Wegovy is right for you, a prescriber still assesses the whole picture.

It is also worth noting that Ozempic, which contains the same active ingredient at different doses, is licensed only for type 2 diabetes. Using it off-label for heart protection is not the same as using a medicine with a heart-indication licence, and the MHRA is clear that these products should not be conflated.

If the cost of private treatment is a practical question as you weigh up your options, our Wegovy cost page sets out how private pricing works and what a legitimate service includes. Treatment for a prescription medicine should be evaluated on clinical suitability first, but cost transparency matters too.

People sometimes ask about semaglutide's effects beyond the heart. Research is ongoing into several body systems, if liver health is a concern alongside cardiovascular risk, our page on whether semaglutide affects the liver covers what is currently known from a UK perspective.

What this means if you are considering semaglutide for weight loss

If you have a cardiovascular history, semaglutide is not a medicine to approach with more caution than others, if anything, the SELECT data suggests it may be particularly relevant. But the right dose, the right timing and the right monitoring are clinical decisions. Your prescriber needs to know about any existing heart conditions, any medicines you take for them (including blood-thinners and antihypertensives), and any symptoms you are currently managing.

Our Wegovy overview page covers eligibility in detail. The full range of weight-management options available through nume, including both injection and tablet formats, is on our treatments page, and a prescriber will help you work out which is right for your situation. If pregnancy is also part of your thinking, semaglutide is not recommended during pregnancy or while breastfeeding; our page on semaglutide and pregnancy covers that clearly.

If you have read this far and still feel uncertain, that is completely understandable. Heart health is not a topic to rush. Speak to our prescribers, the consultation is free, and a real clinician reads every response the same day.